Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01061099 · ClinicalTrials.gov registry record · Phase 1

Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta

A Phase 1 study of Osteogenesis Imperfecta Type II and Osteogenesis Imperfecta Type III, sponsored by Nationwide Children's Hospital.

Completed
Registry status
Phase 1
Development phase
5
Enrollment target
1
Study location

NCT01061099 is a Phase 1 study of Osteogenesis Imperfecta Type II and Osteogenesis Imperfecta Type III that has completed, run by Nationwide Children's Hospital. The registered enrollment target is 5 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01061099, a Phase 1 study of Osteogenesis Imperfecta Type II and Osteogenesis Imperfecta Type III, has completed, sponsored by Nationwide Children's Hospital.

COMPLETED
Registry status
Phase 1
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

This is a study to evaluate the safety and effectiveness of repeated Mesenchymal Stromal Cells (MSC) infusions to patients with Type II or III osteogenesis imperfecta (OI). Participants will receive MSC infusions approximately every 4 months to complete a total of 6 infusions over 20 months. Participants will be followed for 4 months post their last MSC infusion.

Interventions

  • BIOLOGICAL Mesenchymal Stromal Cells

Study Locations (1)

Pennsylvania

  • The Children's Hospital of Philadelphia - Philadelphia

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2010-02
Est. Completion 2014-02
Phase Phase 1

Sponsor

Nationwide Children's Hospital

188 total trials

What the Registry Record Tells You About NCT01061099

The ClinicalTrials.gov registry entry for NCT01061099 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Osteogenesis Imperfecta Type II appearing as the primary indexed condition, and to 1 intervention - of which Mesenchymal Stromal Cells is the first listed.

NCT01061099 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01061099 about?

NCT01061099 is a clinical study titled "Repeated Infusions of Mesenchymal Stromal Cells in Children With Osteogenesis Imperfecta". This is a study to evaluate the safety and effectiveness of repeated Mesenchymal Stromal Cells (MSC) infusions to patients with Type II or III osteogenesis imperfecta (OI). Participants will receive MSC infusions approximately every 4 months to complete a total of 6 infusions over 20 months. Partic...

What is the current status of trial NCT01061099?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2010-02. Estimated completion is 2014-02.

What conditions does trial NCT01061099 study?

This clinical trial studies the following conditions: Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III.

What interventions are being tested in trial NCT01061099?

The interventions under investigation include: Mesenchymal Stromal Cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT01061099?

This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01061099 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.